Page last updated: 2024-11-13
sambutoxin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
sambutoxin: produced by toxic Fusarium isolates, obtained from rotted potato tubers [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 54724817 |
CHEBI ID | 180131 |
MeSH ID | M0240996 |
Synonyms (10)
Synonym |
---|
CHEBI:180131 |
3-[(2s,5r,6r)-6-[(e,4r,6s)-4,6-dimethyloct-2-en-2-yl]-5-methyloxan-2-yl]-4-hydroxy-5-(4-hydroxyphenyl)-1-methylpyridin-2-one |
160047-56-3 |
sambutoxin |
(-)-sambutoxin |
2(1h)-pyridinone, 4-hydroxy-5-(4-hydroxyphenyl)-1-methyl-3-[(2s,5r,6r)-tetrahydro-5-methyl-6-[(1e,3r,5s)-1,3,5-trimethyl-1-hepten-1-yl]-2h-pyran-2-yl]- |
DTXSID001100368 |
4-hydroxy-5-(4-hydroxyphenyl)-1-methyl-3-[(2s,5r,6r)-tetrahydro-5-methyl-6-[(1e,3r,5s)-1,3,5-trimethyl-1-hepten-1-yl]-2h-pyran-2-yl]-2(1h)-pyridinone |
AKOS040762293 |
FS-10439 |
Research Excerpts
Treatment
Excerpt | Reference | Relevance |
---|---|---|
"Treatment with sambutoxin induced the production of ROS, which caused DNA damage." | ( Discovery and Characterization of 4-Hydroxy-2-pyridone Derivative Sambutoxin as a Potent and Promising Anticancer Drug Candidate: Activity and Molecular Mechanism. Cao, ZQ; Cheng, YN; Guo, XL; Li, LN; Wang, L; Zhang, XK, 2018) | 1.06 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
terpene glycoside | A terpenoid in which one or more hydroxy functions are glycosylated. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 20.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.35) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |